China Advanced Const. Mat. Grp Inc (OTC: CADC) plunged 23.20% to $5 in the pre-market session. The 52 week trading range for CADC is $1.01 -$8.50. So far this fiscal, CADC gained 5%. In the last trading session, China Advanced Const. Mat. Grp Inc (OTC: CADC) closed at $6.51.

Tibco Software Inc. (NASDAQ: TIBX) plummeted 2.56% to $9.14 after Goldman Sachs downgraded TIBX from $9.50 to $9. So far this year, TIBX is up 80.73%.

Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) decreased $5.88 or 77% to $1.69 after PARD failed to meet its primary end point of pivotal Phase 3 SPEAR trial Of picoplatin. In the last trading session, PARD ended at $7.58.

Human Genome Sciences (NASDAQ: HGSI) declined 1.04% or $0.29 to $27.60 in the pre-market session after The U.S. health regulators denied approval to Human Genome’s anthrax drug raxibacumab. So far this year, HGSI is up over 1215%.

Shire Plc. (ADR) (NASDAQ: SHPGY) fell 1.82 or $1.09 to $58.71. The 52 week trading range for SHPGY is $31.66 - $60.32. SHPGY closed at $59.80 in the previous trading session.

Activision Blizzard, Inc. (NASDAQ: ATVI) declined 0.09% in the pre-market session and currently trades at $11.68. In the current fiscal, ATVI gained around 35%.

Goldman Sachs has downgraded Tibco Software Inc(NASDAQ: TIBX) to “sell.” The target price for TIBX has been reduced from $9.50 to $9.00.

TIBX’s focus on EPS growth has improved and the company continues to offer best-quality technology in several areas, Goldman Sachs said. Recent market checks, however, have indicated that TIBX continues to face aggressive competition, Goldman Sachs added.

Goldman Sachs believes that Tibco Software’s natural acquirers are concentrating in other areas. For example, Oracle is buying Sun and the likely focus of SAP would be on analytics or SaaS sector rather than TIBCO. Thus, there is limited M&A potential for TIBX in the near term, Goldman Sachs added.